Stress in Couples Undergoing Assisted Reproduction Technology With Different Cycles and Its Impact on Pregnancy Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yimin Zhu, Dr.
- Phone Number: 057189992071
- Email: zhuyim@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Women's Hospital, School of Medicine, Zhejiang University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female partners' >18< 40 years
- Patients undergoing assisted reproductive technology
Exclusion Criteria:
- Female partners with polycystic ovary
- Female partners with insufficiency or premature ovarian failure
- Female partners with endometriosis
- Female partners with abnormal profile of thyroid hormones
- Chromosomal abnormalities of either spouse
- Mental disorder of either spouse
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patients undergoing assisted reproductive technology
Patients undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)
|
Patients are grouped according to the number of IVF/ICSI cycles.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Implantation rate
Time Frame: 6 months
|
Implantation rate is defined as number of sacs per embryo transferred.
|
6 months
|
|
clinical pregnancy rate
Time Frame: 6 months
|
presence of at least one gestational sac on ultrasound of 6 weeks
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of oocytes retrieved
Time Frame: 6 months
|
6 months
|
|
|
fertilization rate
Time Frame: 6 months
|
No. of fertilized oocyte divided by No. of inseminated cumulus-oocyte complexes (COCs)
|
6 months
|
|
cleavage rate
Time Frame: 6 months
|
No. of cleaved embryo divided by No. of fertilized oocyte
|
6 months
|
|
Total gonadotropin use
Time Frame: 6 months
|
Total gonadotropin use of each participant
|
6 months
|
|
Ovarian hyperstimulation syndrome (OHSS) rates
Time Frame: 6 months
|
OHSS rates in both study groups
|
6 months
|
|
Metaphase II (MII) oocytes
Time Frame: 6 months
|
the number of mature oocytes
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Yimin Zhu, Dr., Women's Hospital School Of Medicine Zhejiang University
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20210914
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.